The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

Aggregating and Disaggregating Patients in Clinical Trials and Their Subgroup Analyses

David M. Kent, MD, MS; and Peter K. Lindenauer, MD, MSc
[+] Article, Author, and Disclosure Information

From Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, and Center for Quality of Care Research, Baystate Medical Center, Springfield, MA 01199.

Grant Support: In part by the National Center for Research Resources of the National Institutes of Health (grant UL1RR025752) and the National Institute of Neurological Disorders and Stroke (grant R01 NS062153).

Potential Conflicts of Interest: None disclosed. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-1096.

Requests for Single Reprints: David M. Kent, MD, MS, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Box 63, 800 Washington Street, Boston, MA 02111; e-mail, dkent1@tuftsmedicalcenter.org.

Current Author Addresses: Dr. Kent: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Box 63, 800 Washington Street, Boston, MA 02111.

Dr. Lindenauer: Center for Quality of Care Research, Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199.

Ann Intern Med. 2010;153(1):51-52. doi:10.7326/0003-4819-153-1-201007060-00012
Text Size: A A A

In this issue, Hull and colleagues (1) report on their trial examining venous thromboembolism (VTE) prophylaxis in medical patients. An interim analysis of this trial, performed after enrollment of more than 3000 patients at 370 sites in 20 countries, found a lower-than-anticipated VTE rate (symptomatic or asymptomatic) in those treated with standard enoxaparin prophylaxis (3.3%). In a different context, one might have expected the trial's sponsor, which markets enoxaparin, to have been pleased. However, because this trial was designed to test extended-duration enoxaparin, these results may not have been a cause for celebration. For new therapies, especially those with risks for serious harms, demonstrating benefit is highly dependent on a sufficiently high control rate (2). Rather than simply conclude that standard enoxaparin is highly effective and that the incremental benefits of prolonged therapy would be unlikely to outweigh the additional bleeding risk, the investigators instead set out to identify a subgroup of patients with a higher VTE rate who might be likely to benefit from extended prophylaxis.

First Page Preview

View Large
First page PDF preview


Grahic Jump Location
Sample risk distribution.

The risk distribution in the figure is generated from the following assumptions: 3 risk factors (X, Y, and Z), each of which doubles outcome risk, has a prevalence of 50% and assorts independently. The base risk (with no risk factors) is 1%. If treatment were justified for patients with an outcome risk of 4.5% or greater, sequential one-variable-at-a-time subgroup analyses (on risk factor X, or Y, or Z) would suggest that patients with any one of these risk factors might benefit, together comprising seven eighths of patients. Subgrouping based on a multivariable risk score would demonstrate that only one eighth of patients is at sufficiently high risk to warrant therapy.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.